5月26日,百济神州与安进公司联合宣布,其靶向DLL3/CD3的双特异性抗体药物塔拉妥单抗(tarlatamab)在中国开展的2期临床研究DeLLphi-307取得积极结果,拟用于广泛期小细胞肺癌(ES-SCLC)三线及以上治疗,详细数据将在5月30日开幕的ASCO年会上公布。小细胞肺癌(SCLC)占所有肺癌病例的15%,其中约70%为广泛期(ES-SCLC),具有侵袭性强、易转移、预后差的特点。...
Source Link5月26日,百济神州与安进公司联合宣布,其靶向DLL3/CD3的双特异性抗体药物塔拉妥单抗(tarlatamab)在中国开展的2期临床研究DeLLphi-307取得积极结果,拟用于广泛期小细胞肺癌(ES-SCLC)三线及以上治疗,详细数据将在5月30日开幕的ASCO年会上公布。小细胞肺癌(SCLC)占所有肺癌病例的15%,其中约70%为广泛期(ES-SCLC),具有侵袭性强、易转移、预后差的特点。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.